Metabolite Identification Studies
We can determine the metabolic fate of your molecule or study its activity in cell based systems. Working in collaborative teams, our knowledge base draws from biotransformation specialists alongside biochemists and synthetic/analytical chemists. Our analytical capabilities include high resolution mass spectrometry, NMR and 96 well plate spectrophotometric technology. Both radiolabelled and non-radiolabelled samples are equally accommodated.
The FDA guidance for Safety Testing of Drug Metabolites recommends that the structure of any metabolite which may represent more than 10 % of the exposure in humans should be formally elucidated. The earlier a disproportionate metabolite is recognized and characterised in the drug development process, the lower the risk of downstream delays with better planning of clinical studies.
The expertise and experience, in conjunction with state-of-the-art technology, are available within Arcinova to advise on the optimal approaches for completion of metabolite isolation and identification. Where possible, isolation can be circumvented by hyphenated technologies. The in-house mass spectrometry – Nuclear Magnetic Resonance platform not only enables identification of metabolites, but it permits quantification within a biological matrix.
MHRA SymposiumThe 2018 MHRA Symposium will be attended by John McRoberts, Head of QA.
MHRA SymposiumDates: 20th NovemberLocation: London, UK
AAPS: PharmSci360This years' PharmSci360 conference will be attended by Masha Kononov, Senior Director Emerging Biotech US.
AAPS: PharmSci360Dates: 4th - 7th NovemberLocation: Washington DC, US
Bio-Europe 2018Bio-Europe autumn conference will be attended by Nathalie Huther, Business Development Manager Europe.
Bio-Europe 2018Dates: 5th - 7th NovemberLocation: Copenhagen, Denmark